Supplementary material

Supplementary Table 1. Prevalence of side effects in participants (n=90) after the second dose of Comirnaty vaccine and severity score

Side effects	% of participants			
	Any score	Score 1	Score 2	Score 3
Injection site pain or swelling	84	56	26	3
Injection site redness	20	18	2	0
Injection site pruritus	18	14	3	0
Headache	42	12	22	8
Fatigue	64	20	31	13
Malaise	50	13	24	12
Chills	41	14	22	4
Fever	34	12	17	6
Myalgia	34	10	20	4
Arthralgia	21	7	12	2
Pain in extremity	13	3	8	2
Insomnia	12	6	7	0
Nausea	11	6	4	1
Diarrhea	3	3	0	0
Lymphadenopathy	8	4	3	0
Facial sensitivity disorder	2	2	0	0
Hypersensitivity/allergic reaction	0	0	0	0

Score: 1- mild symptoms that did not disturb daily life; 2- moderate symptoms that somewhat disturbed the activities of daily living; 3- symptoms that last days and/or caused absence from work



Supplementary Figure 1. Antibody dynamics in individual persons.



Supplementary Figure 2 Correlations between age, IgG levels and vaccine side-effects

Higher size and intensity of dots indicates stronger correlation; Blue dot – positive correlation; Red dot – negative correlation

T1 – time-point 1 (before the second dose); T2 – time-point 2 (1 week after the second dose); T3 – time-point 3 (6 weeks after the second dose). Side effects: S1 - Injection site pain or swelling; S2 - Injection site redness; S3 - Injection site pruritus; S4 – Headache; S5 – Fatigue; S6 – Malaise; S7 – Chills; S8 – Fever; S9 – Myalgia; S10 – Arthralgia; S11 - Pain in extremity; S12 – Insomnia; S13 – Nausea; S14 – Diarrhea; S15 – Lymphadenopathy; S16 - Facial sensitivity disorder; S17 - Hypersensitivity/allergic reaction; S_tot – Total side effects score



Supplementary Figure 3. IgG levels comparing persons >40 and ≥40 years old

The group-wise box-plot comparisons of the S-RBD IgG levels in <40 and ≥40 years old vaccinated individuals after the first vaccine dose, 1 and 6 weeks after the second vaccine dose. The brown line and green triangle mark median and mean values, respectively.



Supplementary Figure 4

Principal Component Analysis was performed to reduce the variables containing information of vaccine side effect survey, sex and IgG measurements and understand whether mentioned variables correlate with different age groups. It can be seen from the following visual that patients of 40years and above cluster together. This supports the previous t-test outcome, which resulted in less than 0.05 p-value for two out of three IgG measurements